Loading...

PEPG PEPGEN INC Expansion Plans 8-K Filing

PPGN

PPG

PEPGEN INC

(PEPG)

2025 8-K

Study Results Update

Corporate Update

Financial Results Update

Leadership Change

Financial Results Announced

Option Repricing Approval

Corporate Update

Share Offering Announcement

Splicing Correction Report

Financial Statements

Product Expansion

Financial Statements

Board Appointments

Management Change

Financial Results

Clinical Program Update

FDA Clinical Hold

Financial Results

Conference Announcement

Board Resignation

Management Change

Financial Results Announcement

Clinical Trial Results

Amendment Approval

Financial Results Announcement

Amendments to Bylaws

Other Special Situation

Financial Results Announcement

Other Special Situation

Other Special Situation

Underwriting Agreement

Other Special Situation

Clinical Trial Announcement

Appointment of Director

Financial Results Announcement

FDA Clearance for IND Appli...

Other Special Situation

Presentation of Preclinical...

Equity Offering

Financial Results Announcement

Annual Meeting of Stockholders

Update on Phase 1 Study

FDA Clinical Hold Notice

Clinical Trial Approval

Financial Results Announcement

Regulation FD Disclosure

Financial Results Announcement

External Links:

On May 28, 2025, PepGen Inc. announced it will stop developing PGN-EDO51 for Duchenne muscular dystrophy and focus on its myotonic dystrophy type 1 program after a study showed minimal dystrophin increase. The company plans to report further data from ongoing studies in DM1 later this year and in early 2026.

AI Assistant

PEPGEN INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.